Merck to Acquire EyeBio in a $3 Billion Agreement

Merck, known as MSD outside of the United States and Canada, has announced its definitive agreement to acquire EyeBio, a privately held ophthalmology-focused biotechnology company.

The acquisition, through a Merck subsidiary, entails up to $3 billion, including a $1.3 billion upfront payment and a potential $1.7 billion in milestone payments.

EyeBio is focused on developing therapies targeting retinal diseases, with its lead candidate, Restoret™ (EYE103), showing promise in treating diabetic macular edema and neovascular age-related macular degeneration. The acquisition not only expands Merck's pipeline but also strengthens its presence in ophthalmology.

The transaction is expected to close in the third quarter of 2024 and is subject to customary conditions and regulatory approval. Financial advisors for the acquisition include Citi for Merck and Centerview Partners LLC for EyeBio.